Literature DB >> 28591657

AGC kinases, mechanisms of regulation ‎and innovative drug development.

Alejandro E Leroux1, Jörg O Schulze2, Ricardo M Biondi3.   

Abstract

The group of AGC kinases consists of 63 evolutionarily related serine/threonine protein kinases comprising PDK1, PKB/Akt, SGK, PKC, PRK/PKN, MSK, RSK, S6K, PKA, PKG, DMPK, MRCK, ROCK, NDR, LATS, CRIK, MAST, GRK, Sgk494, and YANK, while two other families, Aurora and PLK, are the most closely related to the group. Eight of these families are physiologically activated downstream of growth factor signalling, while other AGC kinases are downstream effectors of a wide range of signals. The different AGC kinase families share aspects of their mechanisms of inhibition and activation. In the present review, we update the knowledge of the mechanisms of regulation of different AGC kinases. The conformation of the catalytic domain of many AGC kinases is regulated allosterically through the modulation of the conformation of a regulatory site on the small lobe of the kinase domain, the PIF-pocket. The PIF-pocket acts like an ON-OFF switch in AGC kinases with different modes of regulation, i.e. PDK1, PKB/Akt, LATS and Aurora kinases. In this review, we make emphasis on how the knowledge of the molecular mechanisms of regulation can guide the discovery and development of small allosteric modulators. Molecular probes stabilizing the PIF-pocket in the active conformation are activators, while compounds stabilizing the disrupted site are allosteric inhibitors. One challenge for the rational development of allosteric modulators is the lack of complete structural information of the inhibited forms of full-length AGC kinases. On the other hand, we suggest that the available information derived from molecular biology and biochemical studies can already guide screening strategies for the identification of innovative mode of action molecular probes and the development of selective allosteric drugs for the treatment of human diseases.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AGC protein kinase; Allosteric; Drug discovery; PIF-pocket; Regulation

Mesh:

Substances:

Year:  2017        PMID: 28591657     DOI: 10.1016/j.semcancer.2017.05.011

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  39 in total

Review 1.  Targeting the cytoskeleton against metastatic dissemination.

Authors:  Carmen Ruggiero; Enzo Lalli
Journal:  Cancer Metastasis Rev       Date:  2021-01-20       Impact factor: 9.264

Review 2.  Regulation of TORC2 function and localization by Rab5 GTPases in Saccharomyces cerevisiae.

Authors:  Melissa N Locke; Jeremy Thorner
Journal:  Cell Cycle       Date:  2019-05-15       Impact factor: 4.534

Review 3.  Deregulated Protein Kinases: Friend and Foe in Ischemic Stroke.

Authors:  Sandeep Appunni; Deepika Gupta; Muni Rubens; Venkataraghavan Ramamoorthy; Himanshu Narayan Singh; Vishnu Swarup
Journal:  Mol Neurobiol       Date:  2021-09-22       Impact factor: 5.590

4.  Akt Kinase Activation Mechanisms Revealed Using Protein Semisynthesis.

Authors:  Nam Chu; Antonieta L Salguero; Albert Z Liu; Zan Chen; Daniel R Dempsey; Scott B Ficarro; William M Alexander; Jarrod A Marto; Yana Li; L Mario Amzel; Sandra B Gabelli; Philip A Cole
Journal:  Cell       Date:  2018-08-02       Impact factor: 41.582

5.  PDK1 Regulates the Maintenance of Cell Body and the Development of Dendrites of Purkinje Cells by pS6 and PKCγ.

Authors:  Rui Liu; Min Xu; Xiao-Yang Zhang; Min-Jie Zhou; Bing-Yao Zhou; Cui Qi; Bo Song; Qi Fan; Wei-Yan You; Jing-Ning Zhu; Zhong-Zhou Yang; Jun Gao
Journal:  J Neurosci       Date:  2020-06-02       Impact factor: 6.167

6.  Mutations in MAST1 Cause Mega-Corpus-Callosum Syndrome with Cerebellar Hypoplasia and Cortical Malformations.

Authors:  Ratna Tripathy; Ines Leca; Tessa van Dijk; Janneke Weiss; Bregje W van Bon; Maria Christina Sergaki; Thomas Gstrein; Martin Breuss; Guoling Tian; Nadia Bahi-Buisson; Alexander R Paciorkowski; Alistair T Pagnamenta; Andrea Wenninger-Weinzierl; Maria Fernanda Martinez-Reza; Lukas Landler; Stefano Lise; Jenny C Taylor; Gaetano Terrone; Giuseppina Vitiello; Ennio Del Giudice; Nicola Brunetti-Pierri; Alessandra D'Amico; Alexandre Reymond; Norine Voisin; Jonathan A Bernstein; Ellyn Farrelly; Usha Kini; Thomas A Leonard; Stéphanie Valence; Lydie Burglen; Linlea Armstrong; Susan M Hiatt; Gregory M Cooper; Kimberly A Aldinger; William B Dobyns; Ghayda Mirzaa; Tyler Mark Pierson; Frank Baas; Jamel Chelly; Nicholas J Cowan; David Anthony Keays
Journal:  Neuron       Date:  2018-11-15       Impact factor: 17.173

7.  First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors.

Authors:  Robert McLeod; Rajiv Kumar; Dionysis Papadatos-Pastos; Joaquin Mateo; Jessica S Brown; Alvaro H Ingles Garces; Ruth Ruddle; Shaun Decordova; Simone Jueliger; Roberta Ferraldeschi; Oscar Maiques; Victoria Sanz-Moreno; Paul Jones; Stephanie Traub; Gavin Halbert; Sarah Mellor; Karen E Swales; Florence I Raynaud; Michelle D Garrett; Udai Banerji
Journal:  Clin Cancer Res       Date:  2020-07-02       Impact factor: 12.531

8.  mTORC2 controls the activity of PKC and Akt by phosphorylating a conserved TOR interaction motif.

Authors:  Timothy R Baffi; Gema Lordén; Jacob M Wozniak; Andreas Feichtner; Wayland Yeung; Alexandr P Kornev; Charles C King; Jason C Del Rio; Ameya J Limaye; Julius Bogomolovas; Christine M Gould; Ju Chen; Eileen J Kennedy; Natarajan Kannan; David J Gonzalez; Eduard Stefan; Susan S Taylor; Alexandra C Newton
Journal:  Sci Signal       Date:  2021-04-13       Impact factor: 8.192

9.  The 3-phosphoinositide-dependent protein kinase 1 is an essential upstream activator of protein kinase A in malaria parasites.

Authors:  Eva Hitz; Natalie Wiedemar; Armin Passecker; Beatriz A S Graça; Christian Scheurer; Sergio Wittlin; Nicolas M B Brancucci; Ioannis Vakonakis; Pascal Mäser; Till S Voss
Journal:  PLoS Biol       Date:  2021-12-08       Impact factor: 8.029

10.  Non-canonical mTORC2 Signaling Regulates Brown Adipocyte Lipid Catabolism through SIRT6-FoxO1.

Authors:  Su Myung Jung; Chien-Min Hung; Samuel R Hildebrand; Joan Sanchez-Gurmaches; Barbara Martinez-Pastor; Jivani M Gengatharan; Martina Wallace; Dimpi Mukhopadhyay; Camila Martinez Calejman; Amelia K Luciano; Wen-Yu Hsiao; Yuefeng Tang; Huawei Li; Danette L Daniels; Raul Mostoslavsky; Christian M Metallo; David A Guertin
Journal:  Mol Cell       Date:  2019-08-22       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.